Novo starts study to find lowest effective Wegovy pill dose

• Wegovy pill generated sales of 3.22 billion Danish crowns ($499.8 million) in Q2, making it a key investor focus as Novo loses market share to rival Eli Lilly
• The trial will enroll 450 adults with BMI of 30+ (or 27+ with weight-related health issues) who have struggled with dieting, excluding diabetes patients and current GLP-1 medication users
• The study will measure weight loss over 60 weeks compared to placebo, tracking how many patients achieve 5%, 10%, or 15% body weight reduction, though specific dose strengths being tested were not disclosed

Summary: Novo Nordisk Tests Lower Wegovy Pill Doses in New Clinical Trial

Key Development: Novo Nordisk has launched a clinical trial to identify the lowest effective dose of its oral Wegovy weight-loss medication, according to U.S. government clinical trial records.

Market Context: The Danish drugmaker faces intensifying competition from U.S. rival Eli Lilly in the obesity drug market, which analysts project will exceed $100 billion annually by 2030. This trial represents a strategic effort to optimize its product offering as it loses market share.

Financial Performance: Wegovy pill generated 3.22 billion Danish crowns ($499.80 million) in Q2 sales, making it a critical focus for investors.

Trial Details:

• Timeline: Started August 12, 2024; continues through 2028
• Participants: 450 adults (18+) with BMI of 30+ or 27+ with weight-related conditions who have previously failed to lose weight through dieting
• Duration: 60-week study period
• Primary Goal: Determine whether lower doses of oral semaglutide (Wegovy's active ingredient) achieve weight loss superior to placebo
• Secondary Measures: Percentage of patients losing 5%, 10%, or 15% body weight; waist circumference changes; safety profile

Exclusions: Diabetic patients, those with recent significant weight changes, and current GLP-1 medication users will not participate.

Current Dosing: Wegovy pill is approved in 1.5mg, 4mg, 9mg, and 25mg doses, though specific doses being tested were not disclosed.

Market Implications: Finding lower effective doses could improve patient tolerance, reduce side effects, potentially lower costs, and strengthen Novo's competitive position in the rapidly growing obesity treatment market.